Advanced search
Publication Cover
Acta Oncologica Volume 59, 2020 - Issue 4
Journal homepage
802
Views
1
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: TREATMENT PATTERNS AND PROGNOSIS

The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice

Riikka-Liisa K. VuorinenDepartment of Obstetrics and Gynecology, and Tays Cancer Center, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Correspondence[email protected]
,
Tiina H. LuukkaalaResearch, Development and Innovation Center, Tampere University Hospital, Tampere, Finland; ;Faculty of Social Sciences, Tampere University, Tampere, Finland
&
Johanna U. MäenpääDepartment of Obstetrics and Gynecology, and Tays Cancer Center, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland;
Pages 453-457 | Received 13 Sep 2019, Accepted 26 Dec 2019, Published online: 10 Jan 2020

References

  • WHO Statistics. Cancer Today, International Agency for Research on Cancer; [cited 2019 Apr 16]. Available from: http://gco.iarc.fr/today/
  • Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371–1382.
  • Gaitskell K, Martinek I, Bryant A, et al. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2014;9:CD007930.
  • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483.
  • Perren TJ, Swart AM, Pfistere J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
  • Pujade-Lauraine E, Hilpert E, Weber B, et al. Bevacizumab combined with chemotherapy for platinum resistant recurrent ovarian cancer: the AURELIA Open Label Randomized Phase III Trial. J Clin Oncol. 2014;32(13):1302–1308.
  • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
  • Ye Q, Chen H-L. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Arch Gynecol Obstet. 2013;288(3):655–666.
  • Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
  • Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–791.
  • Neyt M, Vlayen J, Devriese S, et al. First- and second-line bevacizumab in ovarian cancer: a Belgian cost-utility analysis. PLoS ONE. 2018;13(4):e0195134.
  • Barnett JC, Secord AA, Cohn DE, et al. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. Cancer. 2013;119(20):3653–3661.
  • Randall L, Burger R, Nguyen H, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol. 2013;130(1):e33–e34.
  • Leminen A, Auranen A, Bützow R, et al. Ovarian cancer. Current care guidelines, The Finnish Medical Society Duodecim, 2012. Duodecim. 2012;128(12):1300–1301.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.